{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:17Z","timestamp":1789726337999,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"vor","delay-in-days":78,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/j.curtheres.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T21:13:37Z","timestamp":1521753217000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study"],"prefix":"10.1016","volume":"88","author":[{"given":"Yoshikazu","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Haruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.curtheres.2018.03.004_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.curtheres.2018.03.004_bib2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015","volume":"51","author":"Iwakiri","year":"2016","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.curtheres.2018.03.004_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/gut.41.4.452","article-title":"Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese","volume":"41","author":"Kinoshita","year":"1997","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.curtheres.2018.03.004_bib4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","article-title":"Epidemiology and clinical characteristics of GERD in the Japanese population","volume":"44","author":"Fujiwara","year":"2009","journal-title":"J Gastroenterol"},{"issue":"suppl","key":"10.1016\/j.curtheres.2018.03.004_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bpg.2004.06.014","article-title":"Are there unmet needs in acid suppression?","volume":"18","author":"Tytgat","year":"2004","journal-title":"Best Prac Res Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.curtheres.2018.03.004_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.curtheres.2018.03.004_bib7","first-page":"145","article-title":"Practical considerations in the management of proton-pump inhibitors","volume":"108","author":"Aguilera-Castro","year":"2016","journal-title":"Rev Esp Enferm Dig"},{"issue":"1","key":"10.1016\/j.curtheres.2018.03.004_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 Years of Proton Pump Inhibitors: A Comprehensive Review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"issue":"10","key":"10.1016\/j.curtheres.2018.03.004_bib9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1046\/j.1365-2036.2000.00840.x","article-title":"CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole","volume":"14","author":"Adachi","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.curtheres.2018.03.004_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1124\/jpet.110.167783","article-title":"E3710, a New Proton Pump Inhibitor, with a Long-Lasting Inhibitory Effect on Gastric Acid Secretion","volume":"334","author":"Kodama","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.curtheres.2018.03.004_bib11","doi-asserted-by":"crossref","unstructured":"Toda R, Miyagawa T, Masuda Y, Hoshino Y, Yoshii K, Hirayama M, et al. Mass Balance and Metabolism of Z-215, a Novel Proton Pump Inhibitor, in Healthy Volunteers. Xenobiotica. 2017; 10.1080\/00498254.2017.1390625.","DOI":"10.1080\/00498254.2017.1390625"},{"key":"10.1016\/j.curtheres.2018.03.004_bib12","doi-asserted-by":"crossref","unstructured":"Toda R, Shiramoto M, Komai E, Yoshii K, Hirayama M, Kawabata Y. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers. J Clin Pharmacol. 2018;58(4):425-433. 10.1002\/jcph.1038","DOI":"10.1002\/jcph.1038"},{"issue":"8","key":"10.1016\/j.curtheres.2018.03.004_bib13","first-page":"1459","article-title":"Endoscopic findings of GERD","volume":"62","author":"Hoshihara","year":"2004","journal-title":"Nippon Rinsho"},{"issue":"suppl 6","key":"10.1016\/j.curtheres.2018.03.004_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2036.2004.02163.x","article-title":"Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders","volume":"20","author":"Robinson","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl 6","key":"10.1016\/j.curtheres.2018.03.004_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2004.02161.x","article-title":"Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole","volume":"20","author":"Horn","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.curtheres.2018.03.004_bib16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0011-393X(02)80085-6","article-title":"Efficacy of rabeprazole in patients with reflux esophagitis: A single-center, open-label, practice-based, postmarketing surveillance investigation","volume":"63","author":"Kinoshita","year":"2002","journal-title":"Curr Ther Res Clin Exp"},{"issue":"7","key":"10.1016\/j.curtheres.2018.03.004_bib17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1440-1746.2012.07121.x","article-title":"Development and evaluation of a modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease to distinguish functional dyspepsia from non-erosive reflux disease","volume":"27","author":"Kusano","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"issue":"suppl B","key":"10.1016\/j.curtheres.2018.03.004_bib18","first-page":"66B","article-title":"Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview","volume":"11","author":"Chiba","year":"1997","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1016\/j.curtheres.2018.03.004_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00007691-199806000-00001","article-title":"Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population","volume":"20","author":"Kimura","year":"1998","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.curtheres.2018.03.004_bib20","first-page":"234","article-title":"Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -A phase III, multicenter, randomized, double-blind trial","volume":"110","author":"Kinoshita","year":"2013","journal-title":"Nippon Shokakibyo Gakkai Zasshi"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X17300747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X17300747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T21:15:28Z","timestamp":1556831728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X17300747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":20,"alternative-id":["S0011393X17300747"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2018.03.004","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}